Stockscreener 앱 받기
24.54
0.21%
0.695
Lyell Immunopharma Inc 주식(LYEL)의 최신 뉴스
A First Look At Lyell Immunopharma (NASDAQ:LYEL) - Seeking Alpha
[EFFECT] Lyell Immunopharma, Inc. SEC Filing - Stock Titan
Lyell Immunopharma (NASDAQ:LYEL) Shares Down 4%Should You Sell? - MarketBeat
Lyell Immunopharma (NASDAQ:LYEL) Stock Price Up 6.9%Should You Buy? - MarketBeat
This WhiteFiber Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday - Sahm
Needham initiates coverage of Lyell Immunopharma (LYEL) with buy recommendation - MSN
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Needham & Company LLC Begins Coverage on Lyell Immunopharma (NASDAQ:LYEL) - MarketBeat
LYEL Earnings History & Surprises | EPS & Revenue Results | LYELL IMMUNOPHARMA INC (NASDAQ:LYEL) - ChartMill
Lyell Immunopharma (NASDAQ:LYEL) Cut to Strong Sell at Zacks Research - Defense World
Signal Recap: Will Lyell Immunopharma Inc outperform tech stocksQuarterly Performance Summary & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn
Lyell Immunopharma Announces Participation in 25th Annual Needham Virtual Healthcare Conference - Sahm
Lyell Immunopharma to Present at 25th Annual Needham Virtual Healthcare Conference - National Today
Cancer drug developer Lyell will webcast a management presentation Apr. 14 - Stock Titan
Head to Head Analysis: Lyell Immunopharma (NASDAQ:LYEL) & Mangoceuticals (NASDAQ:MGRX) - Defense World
Lyell Immunopharma registers 1.95M shares for resale (NASDAQ: LYEL) - Stock Titan
Lyell Immunopharma (NASDAQ:LYEL) Trading Up 9.2%Time to Buy? - MarketBeat
US Stocks Recap: How sensitive is Lyell Immunopharma Inc to inflation2026 Risk Factors & Reliable Entry Point Alerts - baoquankhu1.vn
Lyell Immunopharma (NASDAQ:LYEL) Lowered to Sell Rating by Wall Street Zen - MarketBeat
LYEL Technical Analysis & Stock Price Forecast - Intellectia AI
Lyell Immunopharma: Strong Early CAR-T Data, And Now A More Measured Bet (NASDAQ:LYEL) - Seeking Alpha
H.C. Wainwright reiterates Lyell Immunopharma stock rating at buy By Investing.com - Investing.com Canada
Is Lyell Immunopharma Inc impacted by rising rates2026 Volume Leaders & Low Volatility Stock Suggestions - baoquankhu1.vn
Lyell Immunopharma (LYEL) grants CFO 140,000 stock options - Stock Titan
Lyell Immunopharma (LYEL) CFO Shah identified as insider in Form 3 - Stock Titan
Lyell Immunopharma, Inc. $LYEL Shares Acquired by Foresite Capital Management V LLC - MarketBeat
Citizens reiterates Lyell Immunopharma stock rating on trial progress By Investing.com - ca.investing.com
Lyell Immunopharma closes $50M equity tranche, names new CFO By Investing.com - Investing.com Nigeria
Lyell Immunopharma, Inc. (NASDAQ:LYEL) Short Interest Update - MarketBeat
Lyell Immunopharma: Q4 Earnings Snapshot - theheraldreview.com
Lyell Immunopharma 2025 Annual Report: Advancing Next-Generation CAR T-Cell Therapies for Cancer Treatment - Minichart
Lyell Immunopharma 2025 Financial Results: Annual Loss of $274.4MNews and Statistics - indexbox.io
Lyell Immunopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Lyell Immunopharma (NASDAQ:LYEL) Releases Earnings Results, Misses Expectations By $5.53 EPS - MarketBeat
Lyell Immunopharma: Fourth Quarter Financial Results Overview - Bitget
Lyell Immunopharma misses Q4 revenue estimates - TradingView
Lyell Immunopharma Reports Q4 and Full Year 2025 Business and Financial Results - The Manila Times
LYEL: Pivotal CAR T-cell trials show strong efficacy, with key data updates and solid funding ahead - TradingView
ARCH Venture funds add Lyell (LYEL) stake with 488,090-share buy - Stock Titan
ARCH Venture Fund XIII boosts Lyell (LYEL) stake with 488K-share purchase - Stock Titan
Lyell Immunopharma Appoints Smital Shah as Chief Financial and Business Officer Effective March 2026 - Minichart
Lyell Immunopharma (NASDAQ:LYEL) Shares Gap UpShould You Buy? - MarketBeat
Lyell Immunopharma, Inc. announced that it has received $99.999968 million in funding - marketscreener.com
Citizens Initiates Coverage on LYEL with Market Outperform Ratin - GuruFocus
Lyell Immunopharma (NASDAQ:LYEL) Now Covered by Citizens Jmp - MarketBeat
Lyell names Smital Shah as Chief Financial and Business Officer - TradingView
Lyell Immunopharma (NASDAQ: LYEL) hires Smital Shah as finance chief - Stock Titan
Lyell Immunopharma, Inc. Appoints Smital Shah as Chief Business Officer and Principal Financial Officer, Effective March 9, 2026 - marketscreener.com
Lyell Immunopharma Announces Closing of Additional $50 - GlobeNewswire
Citizens initiates Lyell Immunopharma stock at outperform, $34 target - Investing.com South Africa
Citizens initiates Lyell Immunopharma stock at outperform, $34 target By Investing.com - Investing.com Australia
0.19%
0.63%
자본화:
|
볼륨(24시간):